Frequently asked Questions

About Doptelet and chronic ITP.

Doptelet Hot Air Balloons Flying over Lake

General Doptelet Information

Doptelet® (avatrombopag) is indicated for the treatment of chronic immune thrombocytopenia in adult patients who have had an insufficient response to a previous treatment.1,2

Doptelet is a thrombopoietin receptor agonist (TPO-RA) that works with the body to increase platelet production.1

You may see platelet counts rise in as few as 8 days.1 To read more about the clinical trials and results for Doptelet, visit our efficacy page.

Patients should store Doptelet tablets in the original package and at room temperature, meaning between 68°F to 77°F (20°C to 25°C).1 Please remind patients to store Doptelet, and all medicines, out of the reach of children.

Thrombotic/Thromboembolic Complications: DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease or chronic immune thrombocytopenia. Monitor platelet counts. Monitor for signs and symptoms of thromboembolic events and institute treatment promptly.1

In clinical trials, the most common adverse reactions, which occurred in 10% or more of adults living with low platelets in chronic ITP treated with Doptelet, were: headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae and nasopharyngitis.1 To read more about Doptelet’s adverse reactions, visit our safety page.

Doptelet can be taken with any kind of food to help your patients reach their target platelet count.1 Please note that food is required when taking Doptelet.

General ITP Info

Immune thrombocytopenia (ITP) is an immune disorder characterized by low platelet counts (<100×109/L). The mechanisms of ITP can involve both increased platelet destruction and impaired platelet production.3

Immune thrombocytopenia usually happens when the immune system makes a mistake. It attacks and destroys the cells that help blood clot, also known as platelets.

Common symptoms of immune thrombocytopenia include bruising, petechiae, bleeding, and fatigue.5

Doptelet Dosing

It is recommended to start all patients with a dosage strength of 20 mg once daily and dose adjust as needed. Please note that 20 mg is the initial dose regimen for all patients except those taking moderate or strong dual inducers or moderate or strong dual inhibitors of CYP2C9 and CYP3A4. Depending on your patient’s treatment goal, the dose could be titrated up or down.1 Refer to the Titration Calculator or the Full Prescribing Information for more details on Titration. 

It is recommended that patients take it as soon as they remember, but they should not take 2 doses at one time to make up for a missed dose. It is advised that patients take their next Doptelet dose at their usual scheduled time.1 Refer to the Full Prescribing Information for more information on Doptelet dosing. 

Doptelet may affect the way other medications work, and other medications may affect the way Doptelet works. Dose adjustments are recommended for adult patients living with low platelets in chronic ITP taking moderate or strong dual CYP2C9 and CYP3A4 inducers or inhibitors.1 Refer to the Full Prescribing Information for more information on Doptelet dosing. 

Financial Support

Yes, the Doptelet Copay Assistance Program is for eligible patients who have commercial prescription insurance. Patients may pay as little as $0 per prescription, up to a maximum of $15,000 per calendar year. Visit the access page to view terms and conditions, and learn more about access and reimbursement support from Doptelet Connect

  1. DOPTELET (avatrombopag) [prescribing information]. Durham, NC: AkaRx, Inc; 2021.
  2. DOPTELET (avatrombopag) [patient information leaflet]. Durham, NC: AkaRx, Inc; 2021.
  3. Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017; 129(21):2829-2835. 
  4. Mayo Clinic website. Immune thrombocytopenia (ITP). Published June 8, 2023. Accessed December 19, 2023.
  5. NORD (National Organization for Rare Disorders) website: immune thrombocytopenia. Available at:­diseases/immune-thrombocytopenia/. Accessed May 12, 2021.